hemagglutinin


Also found in: Dictionary, Thesaurus, Medical, Financial, Wikipedia.
Related to hemagglutinin: neuraminidase

hemagglutinin

[‚hē·mə′glüd·ən·ən]
(immunology)
An erythrocyte-agglutinating antibody.
References in periodicals archive ?
These viruses could reassort to create a new virus that had a hemagglutinin from the avian virus and other genes from the human virus.
Complete analysis of the H5 hemagglutinin and N8 neuraminidase phylogenetic trees reveals that the H5N8 subtype has been produced by multiple reassortment events [version 1; referees: 1 approved with reservations].
RIV3 refers to the trivalent recombinant hemagglutinin influenza vaccine, and LAIV and LAIV4 refer to live attenuated influenza vaccine.
This recombinant hemagglutinin vaccine (RIV3) - the first purified, recombinant hemagglutinin (HA) protein influenza vaccine, manufactured without the use of influenza virus - was licensed for adults aged 18-49 years in January 2013.
Of the 24 AIVs, 16 subtypes were detected, representing nine hemagglutinin and seven neuraminidase subtypes.
The use of adjuvant may provide a rapid immune response at a lower hemagglutinin dose than that required in vaccine without adjuvant," said Dr.
The mutation comprised of alterations in the Hemagglutinin protein which allows the virus to infect new hosts.
The specific type of influenza virus is determined by two antigenic surface glycoproteins, neuraminidase (N) and hemagglutinin (H).
one or more of influenza hemagglutinin, influenza nuclear protein, tetanus toxin C-fragment, anthrax protective antigen, HIV gp 120, human carcinoembryonic antigen, and/or a therapeutic, an immunomodulatory gene, such as co-stimulatory gene and/or a cytokine gene.
Laboratory diagnostic techniques used included viral isolation, hemagglutinin inhibition serology, and multiplex, reverse transcription polymerase chain reaction.
The flu vaccine is created by combining Proteosomes(tm) with a purified preparation of influenza proteins that include the hemagglutinin protein.
Developed using Visterra's innovative platform, VIS410 targets a site on influenza hemagglutinin (HA) that is present across all influenza A subtypes and is resistant to mutation development.